Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in locally advanced rectal cancer
NCT05794750Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Apr 2023
- Primary completion
- Apr 2027
- Sponsor
- Jinjing (Beijing) Biotechnology
- Modality
- Bispecific Antibodies
- Drugs
- cadonilimab
- Conditions
- rectal cancer
01
Overview
Phase 2, open-label trial of cadonilimab in rectal cancer, sponsored by Jinjing (Beijing) Biotechnology. Planned start Apr 2023; status: not yet recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients aged 18-75 with stage II/III rectal adenocarcinoma, ECOG 0-1, and no prior immunotherapy or radiation.
04
Registry description
This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with AK104 and chemotherapy + TME surgery in patients with advanced rectal cancer.
Beyond the preview
Go deeper on NCT05794750.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794750.